New HIV drug MK-4646 put through its paces in healthy volunteers
NCT ID NCT07532304
First seen Apr 26, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This early-stage study checks if a new experimental HIV medicine, MK-4646, changes the levels of standard HIV drugs (BIC/FTC/TAF and dolutegravir) in the blood. It involves 16 healthy adults and focuses on safety and how the body processes these drugs together. The results will help plan future studies in people living with HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pinnacle Research Group
RECRUITINGAnniston, Alabama, 36207, United States
Contact
Conditions
Explore the condition pages connected to this study.